Direct acting dopamine agonists are generally less effective than levodopa in relieving symptoms of Parkinson's disease. In an attempt to quantitate and explain this situation, the acute motor responses to intravenous injections of the dopamine agonist, (-)-N-n-propylnorapomorphine hydrochloride (NPA), were compared with those of the dopamine precursor, levodopa. At optimum dose levels, the acute antiParkinsonian efficacy of NPA averaged only about 50% of maximum, while essentially total symptom suppression was obtained with levodopa in patients previously treated with the amine precursor. Dyskinesia severity, however, was similar with the two drugs. group.bmj.com on June 21, 2017 -Published by
Motor fluctuations and dyskinesias eventually complicate the management of most levodopa treated patients with Parkinson's disease.'2 These adverse effects have prompted the search for effective anti-Parkinsonian agents with little or no potential for producing motor response complications. Over the years, many direct acting dopamine agonists have been tested clinically and several are now in general use.''0 All, however, appear to possess less anti-Parkinsonian efficacy than the dopamine precursor, levodopa.'8 "' The basis for this 401 relative lack of efficacy remains essentially speculative. To address this question and to quantitate these differences, the acute motor responses to a dopamine agonist, (-)-Nn-propyl-norapomorphine hydrochloride (NPA),`-`were compared with levodopa in patients at various stages of Parkinson's disease.
Methods
Fifty one patients with idiopathic Parkinson's disease participated in the study after full disclosure of its purposes, risks and potential benefits. Of these, 24 were studied with intravenous NPA, and 36 with intravenous levodopa; nine patients were studied twice, once with NPA and again with levodopa ( Parkinsonian severity was rated by scoring rigidity, tremor and bradykinesia in all four extremities and axial muscles as well as gait difficulty each on a scale of 0 (absent) to 4 (severe), with a maximum score of 64. Similarly, dyskinesias were rated in all four extremities and axial muscles each on a scale of 0 (absent) to 4 (severe), with a maximum score of 20. Motor function was evaluated every 10 minutes following drug administration until returned to baseline. Patient's usual anti-Parkinsonian medications were then resumed for the rest of the day. Anti-Parkinsonian response to each dose was expressed as the improvement at peak action compared with baseline scores. For each patient, optimum dose requirements for both NPA and levodopa were defined as that which produced the greatest reduction in Parkinsonian signs with the least degree of peak-dose choreiform dyskinesias.
On another occasion, five of the subjects participated in studies addressing the possibility of tolerance to NPA within the context of the study design. Each of these subjects received their previously determined optimum dose repeatedly for four consecutive days. Another four patients were studied for the potential motor effects of domperidone. Each was treated with optimum dose levodopa infusion at steady-state for two consecutive days, and received 20 mg [5] Wearing-off 0 35 (0-04) 1 0 (0 1) [8] [12] On-off 0 58 (0-06) 0 9 (0-1) [6] [11]
*Data are means (SEM) for the number of patients in square brackets. Optimum dose is defined as the dose, given as an intravenous bolus, at which best possible anti-Parkinsonian motor response could be achieved with the least degree of adverse effects, including dyskinesias. tANOVA p < 0-003 for difference between on-off group and all other groups.
tDifferences among the groups are not significant.
Results
Comparison of the pharmacological profiles of NPA and levodopa at their respective optimal doses showed both differences and similarities (table 2) . Optimal dose requirements for NPA boluses were significantly higher in patients with on-off phenomenon compared with all other groups. On the other hand, intravenous levodopa doses that produced optimal therapeutic response were essentially equal in all groups (table 2) . Anti-Parkinsonian efficacy at this optimal dose was suboptimal for NPA in all patients groups, averaging about 50%, while that for levodopa was virtually complete, except in levodopa-naive patients (table 3 and fig 1) . Differences in anti-Parkinsonian efficacy of the two drugs were significant for the two fluctuating groups (p < 001). In contrast, NPA and levodopa were equally effective in inducing abnormal involuntary movements, and progressively higher dyskinesia scores were found with worsening response groups; differences between the two drugs were not significant, except for the wearing-off group (p < 0-01). Similarly, the toxic to therapeutic ratio for NPA and levodopa, expressed here as the ratio of dyskinesia scores and per cent antiParkinsonian response at optimal doses were not significantly different, and had the same tendency to progressively worsen with the development and deterioration of motor fluctuations.
Comparison of the quantal dose-response curves for NPA between the four response groups revealed narrowing of the therapeutic window with the development of increasingly severe motor complications (fig 2) . While none Domperidone had no effect on the antiParkinsonian action of levodopa. Mean (SEM) Parkinsonian scores with levodopa and placebo, 3-7 (1 -7) were not significantly different than scores obtained with the combination of levodopa and domperidone, 4-4 (1-3); p > > 0-05. Similarly, dyskinesia scores were not affected 39 (1 4) with placebo, 3-7 (0-9) with domperidone; p > > 0-05. The anti-Parkinsonian efficacy of NPA, like several other direct acting dopamine agonists, appears substantially inferior to that of levodopa.38 The best motor response that could be achieved in response to NPA averaged only about 50% in Parkinsonian patients at any stage of their disease, compared with nearly total symptomatic relief with levodopa in all those previously exposed to the amine precursor. The suboptimal efficacy of dopamine agonists like bromocriptine, lisuride, pergolide and others is well recognised clinically, frequently necessitating co-administration of levodopa.67 10 Despite this discrepancy in antiParkinsonian efficacy between NPA and levodopa, their potential to generate peak-dose dyskinesias did not differ significantly. cent of that of levodopa.'4 The foregoing observations are not influenced by the possibility of tolerance to NPA which has been reported in association with other dopamine agonists, such as apomorphine, when given every few hours."5 In this study, no evidence of tolerance was found when NPA was administered repeatedly as single daily injections. A critical time interval between repeated doses of dopaminomimetics appears necessary for tolerance to develop.'6 Furthermore, the inferior anti-Parkinsonian efficacy of NPA compared with levodopa cannot be due to coadministration of domperidone, since the peripherally acting dopamine antagonist had no effect on the anti-Parkinsonian response to levodopa. [17] [18] [19] Consideration of the pharmacological similarities and differences between NPA, a relatively selective D-2 dopamine agonist,11-13 and levodopa, the prodrug for the 
